CSL Ltd
CSL Limited is an Australia-based biotechnology company.
The business
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Want to buy some cut-price shares?
What would your reaction be if I told you I could get you some shares at a price that is significantly less than what they are actually worth? Well, most people would say here is a wheelbarrow, fill it up with shares but as always there is something of a catch. It is possible to […]
CSL reports 25% profit increase as immunoglobulins and plasma collections lead growth
Biotherapeutics giant CSL (ASX: CSL) has reported a net profit after tax of US$2.64 billion for the 12 months to 30 June, up 25% on a constant currency basis. Net profit after tax before amortisation was US$2.91b (up 15% on a constant currency basis), while revenue for the year was up 11% to US$14.8b. Total […]
CSL profits take US$250m hit from foreign currency movements
Foreign currency movements have dented the forecast profits of multi-national biotechnology company CSL (ASX: CSL) by up to US$250 million. The company this week reported higher-than-expected headwinds, up from an estimated US$175 million reported at the time of its half year results in February. Its constant currency profit guidance for the year remains unchanged, albeit […]
Rio Tinto advances Turquoise Hill takeover, CSL to gain new boss and Telstra issues apology
Rio Tinto’s (ASX: RIO) share price fell at the start of the week, despite a positive update on its proposed takeover of Canadian miner Turquoise Hill Resources. The mining giant announced it received the required support from Turquoise Hill shareholders for its proposed acquisition of the remaining 49% the Canadian miner’s issued and outstanding common […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.